WHO IS SINOMED
SINOMED is a global company engaged in patient-focused medical innovations for interventional medicine. We offer pioneering solutions for treating coronary, neurovascular and structural heart disease. We strive to combine the ingenuity of people with the power of technology to achieve new victories against cardiovascular disease.
The company was founded in 2007 as a startup company searching for a way to improve the common coronary stent. Since its humble beginnings, SINOMED has worked closely with industry thought-leaders expanding its product offering. Today, SINOMED is a publicly traded company on the Shanghai STAR market (Stock Code: 688108.SH) and one of the leaders in the Chinese coronary stent market.